Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease

Completed · Phase 2

Conditions studied: Parkinson's Disease, Parkinsonian Syndrome

In brief

We propose to build on preliminary data evaluating non-dopaminergic/non-motor clinical biomarkers to more fully assess these markers at the threshold of Parkinson disease (PD). Development of reliable biomarkers for both dopaminergic and non-dopaminergic manifestations of Parkinson disease (PD) and related disorders may dramatically accelerate research on PD etiology, pathophysiology, and therapeutics. Biomarkers are broadly defined as characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Specific biomarkers may be useful at the onset of neurodegeneration, the onset of disease, and/or to mark disease progression.

Key facts

Study ID

NCT00315250

Run by

Institute for Neurodegenerative Disorders

People needed

225

Starts

2006-01-01

Expected to finish

2010-06-01

Last updated by the study team

2014-05-09

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Older than 21
• Any parkinsonian symptoms
• Referral by community neurologist
• Parkinsonian symptoms for less than 2 years duration.
• Willingness to follow the study plan.

You may not qualify if…

• Pregnancy
• Significant medical disease including abnormalities on screening biochemical or hematological labs or abnormal electrocardiogram (ECG - tracing of the electrical activity of the heart)

Where it is running

• Institute for Neurodegenerative Disorders — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.